Insecticides India Q3 FY26 Earnings Call Transcript Released

Insecticides (India) Limited has released the transcript of its Earnings Conference Call for the Quarter and Nine Months ended December 31, 2025. The call, which discussed the Unaudited Standalone and Consolidated Financial Results, was held on January 30, 2026. The transcript is available on the company's website.

During the call, the management highlighted that despite a challenging operating environment in Q3 FY26, marked by weak farmer activity and low pest incidence, the company demonstrated resilience, achieving 8% growth. This growth was primarily volume-led and driven by the B2B segment, while the B2C demand remained muted. Gross margins moderated due to a higher B2B share and limited pricing power compared to the previous year. EBITDA and PAT reflected mixed impacts from higher finance and depreciation costs, though strict cost controls and capital discipline were maintained.

The company also reported strong traction from new product launches, including SPARCLE for brown planthopper control in rice. Established brands like Torry and Xplode are expanding their volume. Over the first nine months, five new products were launched, strengthening the portfolio. International markets showed early signs of recovery, with exports expected to stabilize gradually.

For Q4 FY26, the company anticipates a similar environment to Q3, with continued pressure on margins. The strategy focuses on protecting the top line and market share through selective aggression, focused sales pushes, and B2B sales with margin guardrails. Product mix steering towards higher-margin SKUs and strict inventory and working capital controls are also key priorities. The company expects profitability improvement in the medium term, driven by market sentiment, a push towards specialty and branded products, and operational leverage.

The CFO reported that for the 9 months ended FY26, revenue from operations increased by approximately 4% to ₹1,714 crores from ₹1,641 crores in FY25. Gross profit improved by about 7% to ₹546 crores. EBITDA stood at ₹201 crores and PAT at ₹128 crores. The B2C segment contributed around 76% to the performance, B2B 20%, and exports 4%. Premium products accounted for 59% of the B2C portfolio.

Management discussed the impact of potential bans on products like Monocil, estimating a gross sales loss of around ₹75 crores, but expressed confidence in offsetting this through new product launches. The Sotanala technical plant is expected to be operational in 2027, while the formulation facility will start in Q1 of FY27. Raw material prices are considered stable with marginal increases expected post-Chinese New Year. Sales returns for the quarter were ₹50 crores, making the total good return approximately ₹200 crores for the year, which is considered high but in line with industry trends for specific product categories. The company is focusing on increasing its premium product portfolio, aiming for 70% in the medium term, while selectively reducing focus on lower-margin generics.